Cyberloq Technologies, Inc. (CLOQ)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.02	0.02	0	0	0.02
Revenue Growth (YoY)	-	-6.21%	498.77%	1255.84%	-99.01%	-74.16%
Gross Profit	-	0.02	0.02	0	0	0.02
Selling, General & Admin	0.79	0.72	0.34	0.67	0.87	0.38
Research & Development	-	-	0.01	-	0.18	0
Other Operating Expenses	0.03	0.05	0.03	0.01	0.01	0.01
Operating Expenses	0.82	0.77	0.38	0.69	1.06	0.56
Operating Income	-0.82	-0.75	-0.37	-0.68	-1.06	-0.54
Interest Expense	-0.26	-0.24	-0.66	-0.08	-0.02	-0.01
Other Non Operating Income (Expenses)	0	-	-	-	-	0
EBT Excluding Unusual Items	-1.08	-0.99	-1.03	-0.77	-1.08	-0.54
Asset Writedown	-	-	-	-	-	-0.32
Other Unusual Items	-	-	-	-0.21	-0.01	-0.12
Pretax Income	-1.08	-0.99	-1.03	-0.98	-1.09	-0.98
Net Income	-1.08	-0.99	-1.03	-0.98	-1.09	-0.98
Net Income to Common	-1.08	-0.99	-1.03	-0.98	-1.09	-0.98
Shares Outstanding (Basic)	127	126	121	99	78	72
Shares Outstanding (Diluted)	127	126	121	99	78	72
Shares Change (YoY)	4.10%	4.05%	22.69%	25.78%	9.28%	6.67%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	-	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-5019.53%	-2296.32%	-25546.13%	-538311.17%	-2702.63%
Profit Margin	-	-6596.35%	-6418.62%	-36654.74%	-552138.07%	-4930.16%
EBITDA	-	-	-	-	-0.94	-0.42
D&A For EBITDA	-	-	-	-	0.12	0.12
EBIT	-0.82	-0.75	-0.37	-0.68	-1.06	-0.54
Revenue as Reported	-	0.02	0.02	0	0	0.02
Advertising Expenses	-	0	0	0.01	0.01	0.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.